Study summary

JAK inhibitor pills markedly improved dermatomyositis skin disease

JAK inhibitor meta-analysis · 7 studies, 91 people · Published March 2024, Frontiers in Immunology

17.67point drop in skin disease score (CDASI)

What was tested

A pooled analysis of studies of JAK inhibitors (tofacitinib, ruxolitinib, baricitinib) for dermatomyositis and polymyositis.

What they found

Skin disease activity (CDASI) fell by 17.67 points on average.
Serious side effects were uncommon in these small studies.

What it means

Small, early studies that set the stage for the brepocitinib phase 3 trial.

Front Immunol, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.